| NASDAQ (usa) |
|
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
![]() |
7487.96 | -5.12 | -0.07% |
| DAX (german) |
|
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Genfit SA (PA: GNFT)
GNFT Technical Analysis
4
| As on 13th Nov 2025 GNFT STOCK Price closed @ 3.72 and we RECOMMEND Sell for LONG-TERM with Stoploss of 3.93 & Strong Sell for SHORT-TERM with Stoploss of 3.94 we also expect STOCK to react on Following IMPORTANT LEVELS. |
GNFTSTOCK Price
| Open | 3.79 | Change | Price | % |
| High | 3.80 | 1 Day | -0.07 | -1.85 |
| Low | 3.71 | 1 Week | 0.13 | 3.62 |
| Close | 3.72 | 1 Month | 0.22 | 6.29 |
| Volume | 76344 | 1 Year | -0.94 | -20.17 |
| 52 Week High 5.70 | 52 Week Low 2.90 | ||||
PA France Most Active Stocks
| ALADO | 0.00 | % |
| FTI | 5.91 | -1.66% |
| VIEDS | 0.72 | 4.35% |
| ALBOO | 0.00 | % |
| CGG | 0.69 | -2.82% |
| ACA | 16.53 | 1.85% |
| ALHYG | 0.01 | 0.00% |
| ALTBG | 2.88 | % |
| CS | 38.95 | 1.06% |
| ENGI | 21.93 | 1.20% |
PA France Top Gainers Stocks
PA France Top Losers Stocks
| GNFT Daily Charts |
GNFT Intraday Charts |
Whats New @ Bazaartrend |
GNFT Free Analysis |
|
|
GNFT Important Levels Intraday
| RESISTANCE | 3.89 |
| RESISTANCE | 3.84 |
| RESISTANCE | 3.80 |
| RESISTANCE | 3.77 |
| SUPPORT | 3.67 |
| SUPPORT | 3.64 |
| SUPPORT | 3.60 |
| SUPPORT | 3.55 |
GNFT Forecast November 2025
| 4th UP Forecast | 5.2 |
| 3rd UP Forecast | 4.73 |
| 2nd UP Forecast | 4.43 |
| 1st UP Forecast | 4.14 |
| 1st DOWN Forecast | 3.3 |
| 2nd DOWN Forecast | 3.01 |
| 3rd DOWN Forecast | 2.71 |
| 4th DOWN Forecast | 2.24 |
GNFT Weekly Forecast
| 4th UP Forecast | 4.82 |
| 3rd UP Forecast | 4.47 |
| 2nd UP Forecast | 4.25 |
| 1st UP Forecast | 4.03 |
| 1st DOWN Forecast | 3.41 |
| 2nd DOWN Forecast | 3.19 |
| 3rd DOWN Forecast | 2.97 |
| 4th DOWN Forecast | 2.62 |
GNFT Forecast2025
| 4th UP Forecast | 9.96 |
| 3rd UP Forecast | 7.96 |
| 2nd UP Forecast | 6.72 |
| 1st UP Forecast | 5.49 |
| 1st DOWN Forecast | 1.95 |
| 2nd DOWN Forecast | 0.72 |
| 3rd DOWN Forecast | -0.52 |
| 4th DOWN Forecast | -2.52 |
Genfit SA ( PA France Symbol : GNFT )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
GNFT Other Details
| Segment | EQ | |
| Market Capital | 141798032.00 | |
| Sector | Healthcare | |
| Industry | Biotechnology | |
| Offical website | > echo $website ; ?> | |
GNFT Address
![]() |
||
GNFT Latest News
GNFT Business Profile
Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France. Address: Parc EurasantE, Loos, France, 59120
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service

